大紀事

公告本公司董事會決議辦理現金增資發行新股

公告本公司董事會追認修訂114年度員工認股權憑證發行及認 股辦法

Announcement: Two Foam Wound Dressing Products Approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and Granted Class I Medical Device Sales Authorization

Announcement: Key Resolutions of the 2025 Annual General Meeting.

Announcement: List of Elected Directors (Including Independent Directors) from the 2025 Annual General Meeting By-Election.

Announcement: Changes in the Membership of the Company's 3rd Term Audit Committee.

Announcement: Approval of Lifting Non-Competition Restrictions for Newly Elected Directors (Including Independent Directors) at the 2025 Annual General Meeting.

AMS BioteQ SIPSIP Pro Gelatin Dressing: Innovative Technology Ushers in a New Era of Wound Care.

AMS BioteQ (6864-TW) Announces Signing of MOUs with Four Healthcare and Medical Equipment Distributors in the Middle East.

AMS BioteQ (6864-TW) debuts its innovative horticultural product "SeepPlug" – a breakthrough in medical material technology – at the Taiwan International Orchid Show.

Announcement of Board Resolution on Public Offering Prior to Listing (OTC Listing), with Waiver of Preemptive Rights by Existing Shareholders.

Announcement of Board Resolution to Terminate the Private Placement of Common Shares Approved at the 2024 Annual Shareholders' Meeting.

Announcement of Board Resolution on Private Placement of Common Shares.

Announcement of Board Approval of 2024 Individual Financial Statements.

Announcement of Board Resolution on Change of Representative for Tokyo Branch, Japan.

Announcement regarding the resolution of the Board of Directors to convene the 2025 Annual General Meeting of Shareholders.

The company's board of directors has resolved not to distribute dividends.

Announcement of Key Resolutions from the First Extraordinary Shareholders' Meeting of 2025.

Announcement of Elected Directors (Including Independent Directors) from the First Extraordinary Shareholders' Meeting of 2025.

Announcement of the Election of Chairman of the Board.

Announcement of the Third-Term Audit Committee Members.

Announcement of the Third-Term Remuneration Committee Members.

Announcement on the Approval of Lifting Non-Competition Restrictions for New Directors (Including Independent Directors) at the Company's First Extraordinary Shareholders' Meeting of 2025.

AMS BioteQ has officially joined the Japan Life Science Association (Link-J) as a member.

Notice Regarding the Completion of Cash Capital Increase and Determination of Capital Increase Record Date for Year 2024.

Seizing the overseas dressing market, AMS BioteQ obtains its first distribution contract in Japan.

AMS BioteQ (TPE:6864) will conduct a rights issue of 40 million NT dollars, with the ex-rights date on September 12. The issue price is set at 28 NT dollars per share.

The board of directors of AMS BioteQ (TPE:6864) approved the appointment of Deputy General Manager Zhang Yiwei.

AMS BioteQ (TPE:6864) has resolved to issue 4 million new shares, with a tentative price of 28 NT dollars per share. Each thousand shares can subscribe for approximately 119.95 shares.

Officially signed a distributor agreement with VITAHOUSE PHARAC PTY CO., LIMITED for the mainland region.

SIPSIP Foam has obtained Class I medical device sales approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

The decision of the AMS BioteQ Board of Directors to establish a branch office in Tokyo, Japan and appoint a representative for the branch office.

Announcement of the Board Resolution of AMS BioteQ Regarding the Convening of the 113th Annual Shareholders' Meeting

The board of directors of AMS BioteQ has resolved to issue common shares by way of a private placement.

AMS BioteQ was invited to exhibit at the inaugural Japan Pharmaceutical Exhibition.

"Artificial Dressing and Its Application for Promoting Wound Healing" "patent approved by the United States Patent and Trademark Office."

Signed a memorandum of understanding (MOU) on industry-academic collaboration with the School of Pharmacy, Kaohsiung Medical University, to enhance industry-academic exchanges.

The capital increase case for the year 112, with a fund of 75 million NTD, has been fully subscribed, and the capital increase base date is set on 1st February.

"Artificial Dressing and Its Application for Promoting Wound Healing" has successfully obtained approval for a new invention patent in Taiwan.

SIPSIP™ Foam, the AMS BioteQ wound dressing, has successfully obtained FDA registration.

SIPSIP™ Foam successfully obtained the TFDA medical device approval.

Debuted SIPSIPᵀᴹ Series dressing at Medical Japan 2023 Tokyo.

Collaboration with Kaohsiung Medical University and Thailand's Chulalongkorn University for the development of inhibiting Dengue virus DENV-2 experiment.

Issued the first employee stock warrants in 2023.

Collaboration with Kaohsiung Medical University and Mahidol University (Thailand) to develop anti-avian influenza drugs.

Setting up the Quality Management System (QMS).

Setting up the Audit and Compensation Committees, and listing on the Emerging Stock Market.

Issued the first employee stock warrants for 10M (NTD) in 2021.

The stocks were entirely replaced without physical certificates.

Implemented a cash capital increment of 90M (NTD), leading to an augmented paid-in capital of 250M (NTD) subsequent to the increment.

IPO to Taipei Exchange: Stock Symbol 6864

Announced collaboration with National Taiwan University College of Medicine for testing YUAN-03 in prevention and treatment of SARS-CoV-2. At the effective dose of 75ppm, the virus inhibition rate is almost 100%.

Announced collaboration with the Institute of Biotechnology and Pharmaceutical Research, NHRI. Passed testing against HCoV-OC43 with 50ppm effective dose, achieving 100% virus inhibition rate.

Implemented a cash capital increment of 80M (NTD), leading to an augmented paid-in capital of 160M (NTD) subsequent to the increment.

Awarded the subsidy for the project 'Development of Hydrogel Spray with Natural Antimicrobial High Polymer Material,' granted by the Ministry of Economic Affairs, under the SBIR P1 program.

Awarded the subsidy for the project 'Development of Feed Additive Using Edible Probiotic Fermentation Technology,' granted by the Ministry of Economic Affairs, under the SBIR S1 program.

Awarded the subsidy for the project 'Development of Immune-Modulating Feed Additives Using Edible Probiotic Technology', granted by the Industrial Development Administration, Ministry of Economic Affairs, under the CITD program.

Formation of RD base in Southern Taiwan Science Park.

Implemented a cash capital increment of 79.95M (NTD), leading to an augmented paid-in capital of 80M (NTD) subsequent to the increment.

Successfully transferred technology from National Chung Hsing University for the formulation and production method of Streptomyces Padanus PMS-702 for plant protection.

Formation of AMS BioteQ Co., Ltd.